Free Trial

electroCore, Inc. (NASDAQ:ECOR) Shares Acquired by Renaissance Technologies LLC

electroCore logo with Medical background

Renaissance Technologies LLC grew its stake in electroCore, Inc. (NASDAQ:ECOR - Free Report) by 80.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 131,786 shares of the company's stock after buying an additional 58,800 shares during the period. Renaissance Technologies LLC owned 1.98% of electroCore worth $2,136,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its holdings in electroCore by 31,250.0% during the fourth quarter. JPMorgan Chase & Co. now owns 3,762 shares of the company's stock worth $61,000 after buying an additional 3,750 shares during the last quarter. DnB Asset Management AS purchased a new stake in shares of electroCore in the fourth quarter worth about $180,000. Finally, Geode Capital Management LLC lifted its holdings in shares of electroCore by 10.3% in the third quarter. Geode Capital Management LLC now owns 63,485 shares of the company's stock worth $458,000 after buying an additional 5,951 shares in the last quarter. Institutional investors and hedge funds own 26.74% of the company's stock.

electroCore Stock Performance

NASDAQ ECOR traded down $0.14 on Thursday, reaching $7.22. 10,279 shares of the stock traded hands, compared to its average volume of 137,192. electroCore, Inc. has a 12 month low of $5.02 and a 12 month high of $19.49. The company has a fifty day moving average price of $8.84 and a 200-day moving average price of $12.23. The company has a market cap of $51.90 million, a price-to-earnings ratio of -3.94 and a beta of 0.83.

Insider Activity at electroCore

In other electroCore news, Director Thomas J. Errico bought 6,000 shares of the company's stock in a transaction dated Monday, March 17th. The stock was acquired at an average price of $8.10 per share, with a total value of $48,600.00. Following the completion of the acquisition, the director now directly owns 256,401 shares of the company's stock, valued at $2,076,848.10. This represents a 2.40 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 19.70% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts have recently commented on ECOR shares. HC Wainwright reaffirmed a "buy" rating and set a $25.00 price objective on shares of electroCore in a research note on Thursday, March 13th. LADENBURG THALM/SH SH cut their target price on shares of electroCore from $28.00 to $26.00 and set a "buy" rating for the company in a research report on Thursday, March 13th.

View Our Latest Report on ECOR

electroCore Profile

(Free Report)

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.

Featured Stories

Institutional Ownership by Quarter for electroCore (NASDAQ:ECOR)

Should You Invest $1,000 in electroCore Right Now?

Before you consider electroCore, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and electroCore wasn't on the list.

While electroCore currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in May 2025
3 Stocks Offering Rare Generational Buying Opportunities
Make Your Money Work Harder: The Power of Dividend Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines